POINT Biopharma Global Inc.
NASDAQ: PNT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Joe A. McCann
- Employees
- 129
- Headquarters
- Indianapolis, United States
- IPO year
- 2020
- Market cap
- $1.3B
- Website
- https://www.pointbiopharma.com
Loading PNT…
Loading profile data…Frequently asked questions about PNT
What does POINT Biopharma Global Inc. (PNT) do?
POINT Biopharma Global Inc. functions as a radiopharmaceutical company dedicated to the advancement and commercialization of specialized radioligand therapies designed to combat various cancerous conditions. Its two primary investigational treatments, both currently in Phase III clinical trials, are PNT2002, a radioligand engineered to target pr...
Where does PNT trade?
POINT Biopharma Global Inc. (PNT) trades on the NASDAQ Capital Market.
What sector is PNT in?
POINT Biopharma Global Inc. (PNT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of POINT Biopharma Global Inc.?
Joe A. McCann is the chief executive officer of POINT Biopharma Global Inc. (PNT).
Where is POINT Biopharma Global Inc. headquartered?
POINT Biopharma Global Inc. is headquartered in United States.
Does PNT pay a dividend?
POINT Biopharma Global Inc. (PNT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PNT go public?
POINT Biopharma Global Inc. (PNT) completed its initial public offering in 2020.